Supplementary Materials for
Consolidated Financial Results for
the 2nd Quarter of Fiscal Year 2021. 12 (IFRS)
Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
- Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
- Exchange rates used for each period are as follows.
QTR | (Yen) | |||||||||||
Actual* | Actual* | |||||||||||
FY2020 | FY2021 | |||||||||||
1-3 | 4-6 | 7-9 | 10-12 | 1-3 | 4-6 | 7-9 | 10-12 | |||||
QTR | QTR | QTR | QTR | QTR | QTR | QTR | QTR | |||||
CHF | 112.61 | 111.54 | 115.39 | 115.52 | 117.08 | 120.11 | ||||||
EUR | 120.19 | 118.35 | 124.06 | 124.51 | 127.65 | 131.87 | ||||||
USD | 109.02 | 107.53 | 106.16 | 104.50 | 105.83 | 109.44 | ||||||
SGD | 78.72 | 76.15 | 77.23 | 77.58 | 79.47 | 82.12 | ||||||
*Market average exchange rate | ||||||||||||
YTD | ||||||||||||
Actual* | Actual* | Actual* | Assumption | |||||||||
FY2019 | FY2020 | FY2021 | FY2021 | |||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-12 | |||
Full-year | YTD | YTD | YTD | Full-year | YTD | YTD | YTD | Full-year | Full-year | |||
CHF | 109.72 | 112.61 | 112.07 | 113.14 | 113.72 | 117.08 | 118.60 | 116.00 | ||||
EUR | 122.08 | 120.19 | 119.27 | 120.80 | 121.69 | 127.65 | 129.76 | 126.00 | ||||
USD | 109.05 | 109.02 | 108.28 | 107.57 | 106.80 | 105.83 | 107.63 | 105.00 | ||||
SGD | 79.94 | 78.72 | 77.42 | 77.36 | 77.41 | 79.47 | 80.80 | 78.00 | ||||
*Market average exchange rate | ||||||||||||
Period-end | ||||||||||||
Actual | Actual | Actual | ||||||||||
FY2019 | FY2020 | FY2021 | ||||||||||
31 Dec. | 31 Mar. | 30 Jun. | 30 Sep. | 31 Dec. | 31 Mar. | 30 Jun. | 30 Sep. | 31 Dec. | ||||
CHF | 112.31 | 112.49 | 113.07 | 114.92 | 117.10 | 117.14 | 120.02 | |||||
EUR | 121.93 | 119.13 | 120.93 | 124.08 | 126.89 | 129.30 | 131.48 | |||||
USD | 108.88 | 107.83 | 107.57 | 105.66 | 103.19 | 110.37 | 110.52 | |||||
SGD | 80.72 | 75.73 | 77.18 | 77.19 | 77.98 | 81.87 | 82.15 |
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 2nd quarter of FY2021(IFRS) | 1 |
Reconciliation of IFRS results to Core results
(Billions of yen) | |||||||||||
FY2020 | FY2021 | ||||||||||
1-6 | 1-6 | ||||||||||
IFRS results | Intangible | Others | Core results | IFRS results | Intangible | Others | Core results | ||||
assets | assets | ||||||||||
Revenues | 368.1 | - | - | 368.1 | 390.2 | - | - | 390.2 | |||
Sales | 305.7 | - | - | 305.7 | 304.1 | - | - | 304.1 | |||
Royalties and other operating income | 62.5 | - | - | 62.5 | 86.1 | - | - | 86.1 | |||
Cost of sales | (131.8) | 0.6 | - | (131.2) | (123.4) | 1.5 | - | (121.9) | |||
Gross profit | 236.3 | 0.6 | - | 236.9 | 266.8 | 1.5 | - | 268.4 | |||
Operatingexpenses | (95.7) | 0.2 | 2.3 | (93.2) | (106.2) | 1.6 | 2.0 | (102.5) | |||
Marketing and distribution | (32.8) | - | 0.5 | (32.3) | (33.8) | - | (0.2) | (34.0) | |||
Research and development | (54.9) | 0.2 | 1.8 | (52.9) | (63.3) | 1.6 | 1.9 | (59.9) | |||
General and administration | (8.0) | - | 0.0 | (8.0) | (9.1) | - | 0.4 | (8.7) | |||
Operating profit | 140.6 | 0.8 | 2.3 | 143.7 | 160.7 | 3.1 | 2.0 | 165.8 | |||
Financing costs | (0.0) | - | - | (0.0) | (0.0) | - | - | (0.0) | |||
Other financial income (expense) | (0.2) | - | - | (0.2) | 0.6 | - | - | 0.6 | |||
Other expense | (0.9) | - | - | (0.9) | (0.0) | - | - | (0.0) | |||
Profitbefore taxes | 139.6 | 0.8 | 2.3 | 142.7 | 161.3 | 3.1 | 2.0 | 166.4 | |||
Income taxes | (37.3) | (0.2) | (0.7) | (38.2) | (43.1) | (0.9) | (0.6) | (44.7) | |||
Net income | 102.3 | 0.6 | 1.6 | 104.5 | 118.1 | 2.2 | 1.4 | 121.7 | |||
Attributable to | |||||||||||
Chugai shareholders | 102.3 | 0.6 | 1.6 | 104.5 | 118.1 | 2.2 | 1.4 | 121.7 | |||
Non-controlling interests | - | - | - | - | - | - | - | - |
Core results
Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.
The table above shows the reconciliation of IFRS results into Core results. The detail is as below.
Intangible assets
Amortization (0.7 billion yen in 2020 and 1.5 billion yen in 2021)
Impairment (0.1 billion yen in 2020 and 1.6 billion in 2021)
Others
Restructuring expenses etc.(2.3 billion yen in 2020 and 2.0 billion yen in 2021)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 2nd quarter of FY2021(IFRS) | 2 | |||||||||||||||||
IFRS results (QTR) | ||||||||||||||||||
(Billions of yen) | ||||||||||||||||||
Actual | Actual | |||||||||||||||||
FY2020 | FY2021 | |||||||||||||||||
1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change | 4-6 | Change | 7-9 | Change | 10-12 | Change | |||||||
QTR | QTR | QTR | QTR | QTR | (%) | QTR | (%) | QTR | (%) | QTR | (%) | |||||||
Revenues | 179.4 | 188.7 | 208.4 | 210.4 | 168.8 | (5.9) | 221.4 | +17.3 | ||||||||||
Sales | 144.5 | 161.1 | 159.1 | 168.5 | 130.3 | (9.8) | 173.9 | +7.9 | ||||||||||
Domestic | 101.9 | 102.7 | 98.6 | 105.9 | 94.9 | (6.9) | 108.5 | +5.6 | ||||||||||
Overseas | 42.6 | 58.4 | 60.6 | 62.6 | 35.4 | (16.9) | 65.3 | +11.8 | ||||||||||
Royalties and other operating income | 34.9 | 27.6 | 49.3 | 41.9 | 38.6 | +10.6 | 47.5 | +72.1 | ||||||||||
Royalty and profit-sharing income | 26.4 | 27.1 | 35.6 | 40.5 | 36.6 | +38.6 | 46.7 | +72.3 | ||||||||||
Other operating income | 8.5 | 0.5 | 13.6 | 1.4 | 2.0 | (76.5) | 0.8 | +60.0 | ||||||||||
Cost of sales | (61.3) | (70.6) | (69.4) | (72.3) | (55.3) | (9.8) | (68.1) | (3.5) | ||||||||||
(% of Sales) | 42.4 | 43.8 | 43.6 | 42.9 | 42.4 | - | 39.2 | - | ||||||||||
Gross profit | 118.2 | 118.1 | 139.0 | 138.2 | 113.5 | (4.0) | 153.4 | +29.9 | ||||||||||
(% of Revenues) | 65.9 | 62.6 | 66.7 | 65.7 | 67.2 | - | 69.3 | - | ||||||||||
Operating expenses | (45.7) | (49.9) | (52.4) | (64.2) | (49.5) | +8.3 | (56.6) | +13.4 | ||||||||||
(% of Revenues) | 25.5 | 26.4 | 25.1 | 30.5 | 29.3 | - | 25.6 | - | ||||||||||
Marketing and distribution | (15.8) | (17.0) | (17.0) | (22.8) | (15.9) | +0.6 | (17.9) | +5.3 | ||||||||||
(% of Revenues) | 8.8 | 9.0 | 8.2 | 10.8 | 9.4 | - | 8.1 | - | ||||||||||
Research and development | (26.1) | (28.8) | (30.1) | (32.8) | (29.7) | +13.8 | (33.6) | +16.7 | ||||||||||
(% of Revenues) | 14.5 | 15.3 | 14.4 | 15.6 | 17.6 | - | 15.2 | - | ||||||||||
General and administration | (3.9) | (4.1) | (5.2) | (8.6) | (3.9) | 0.0 | (5.2) | +26.8 | ||||||||||
(% of Revenues) | 2.2 | 2.2 | 2.5 | 4.1 | 2.3 | - | 2.3 | - | ||||||||||
Operating profit | 72.4 | 68.2 | 86.7 | 73.9 | 64.0 | (11.6) | 96.7 | +41.8 | ||||||||||
(% of Revenues) | 40.4 | 36.1 | 41.6 | 35.1 | 37.9 | - | 43.7 | - | ||||||||||
Financing costs | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | 0.0 | (0.0) | 0.0 | ||||||||||
Other financial income (expense) | (0.6) | 0.5 | (0.8) | (0.5) | 0.3 | - | 0.3 | (40.0) | ||||||||||
Other expense | (0.5) | (0.3) | (0.3) | (0.4) | - | - | (0.0) | (100.0) | ||||||||||
Profit before taxes | 71.2 | 68.4 | 85.6 | 73.1 | 64.2 | (9.8) | 97.0 | +41.8 | ||||||||||
(% of Revenues) | 39.7 | 36.2 | 41.1 | 34.7 | 38.0 | - | 43.8 | - | ||||||||||
Income taxes | (19.7) | (17.6) | (25.4) | (20.7) | (16.8) | (14.7) | (26.3) | +49.4 | ||||||||||
Net income | 51.5 | 50.8 | 60.1 | 52.3 | 47.4 | (8.0) | 70.7 | +39.2 | ||||||||||
(% of Revenues) | 28.7 | 26.9 | 28.8 | 24.9 | 28.1 | - | 31.9 | - | ||||||||||
Attributable to | ||||||||||||||||||
Chugai shareholders | 51.5 | 50.8 | 60.1 | 52.3 | 47.4 | (8.0) | 70.7 | +39.2 | ||||||||||
Non-controlling interests | - | - | - | - | - | - | - | - | ||||||||||
Earnings per share | ||||||||||||||||||
Basic (yen) | 31.37 | 30.89 | 36.58 | 31.82 | 28.84 | (8.1) | 43.02 | +39.3 | ||||||||||
Diluted (yen) | 31.33 | 30.85 | 36.55 | 31.80 | 28.82 | (8.0) | 42.99 | +39.4 |
Other financial income (expense) includes net amount of FX related gains/losses.
Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. "Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 2nd quarter of FY2021(IFRS) | 3 | |||||||||||||||||
IFRS results (YTD) | ||||||||||||||||||
(Billions of yen) | ||||||||||||||||||
Actual | Actual | Actual | ||||||||||||||||
FY2019 | FY2020 | FY2021 | ||||||||||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change | 1-6 | Change | 1-9 | Change | 1-12 | Change | ||||||
YTD | YTD | YTD | YTD | YTD | YTD | (%) | YTD | (%) | YTD | (%) | YTD | (%) | ||||||
Revenues | 686.2 | 179.4 | 368.1 | 576.5 | 786.9 | 168.8 | (5.9) | 390.2 | +6.0 | |||||||||
Sales | 588.9 | 144.5 | 305.7 | 464.8 | 633.3 | 130.3 | (9.8) | 304.1 | (0.5) | |||||||||
Domestic | 437.6 | 101.9 | 204.6 | 303.2 | 409.1 | 94.9 | (6.9) | 203.4 | (0.6) | |||||||||
Overseas | 151.3 | 42.6 | 101.0 | 161.6 | 224.2 | 35.4 | (16.9) | 100.7 | (0.3) | |||||||||
Royalties and other operating income | 97.3 | 34.9 | 62.5 | 111.7 | 153.6 | 38.6 | +10.6 | 86.1 | +37.8 | |||||||||
Royalty and profit-sharing income | 76.5 | 26.4 | 53.5 | 89.1 | 129.6 | 36.6 | +38.6 | 83.3 | +55.7 | |||||||||
Other operating income | 20.8 | 8.5 | 9.0 | 22.6 | 24.1 | 2.0 | (76.5) | 2.8 | (68.9) | |||||||||
Cost of sales | (266.1) | (61.3) | (131.8) | (201.2) | (273.5) | (55.3) | (9.8) | (123.4) | (6.4) | |||||||||
(% of Sales) | 45.2 | 42.4 | 43.1 | 43.3 | 43.2 | 42.4 | - | 40.6 | - | |||||||||
Gross profit | 420.1 | 118.2 | 236.3 | 375.3 | 513.5 | 113.5 | (4.0) | 266.8 | +12.9 | |||||||||
(% of Revenues) | 61.2 | 65.9 | 64.2 | 65.1 | 65.3 | 67.2 | - | 68.4 | - | |||||||||
Operating expenses | (209.5) | (45.7) | (95.7) | (148.0) | (212.3) | (49.5) | +8.3 | (106.2) | +11.0 | |||||||||
(% of Revenues) | 30.5 | 25.5 | 26.0 | 25.7 | 27.0 | 29.3 | - | 27.2 | - | |||||||||
Marketing and distribution | (77.2) | (15.8) | (32.8) | (49.8) | (72.6) | (15.9) | +0.6 | (33.8) | +3.0 | |||||||||
(% of Revenues) | 11.3 | 8.8 | 8.9 | 8.6 | 9.2 | 9.4 | - | 8.7 | - | |||||||||
Research and development | (107.9) | (26.1) | (54.9) | (85.0) | (117.9) | (29.7) | +13.8 | (63.3) | +15.3 | |||||||||
(% of Revenues) | 15.7 | 14.5 | 14.9 | 14.7 | 15.0 | 17.6 | - | 16.2 | - | |||||||||
General and administration | (24.4) | (3.9) | (8.0) | (13.2) | (21.8) | (3.9) | 0.0 | (9.1) | +13.8 | |||||||||
(% of Revenues) | 3.6 | 2.2 | 2.2 | 2.3 | 2.8 | 2.3 | - | 2.3 | - | |||||||||
Operating profit | 210.6 | 72.4 | 140.6 | 227.3 | 301.2 | 64.0 | (11.6) | 160.7 | +14.3 | |||||||||
(% of Revenues) | 30.7 | 40.4 | 38.2 | 39.4 | 38.3 | 37.9 | - | 41.2 | - | |||||||||
Financing costs | (0.1) | (0.0) | (0.0) | (0.0) | (0.1) | (0.0) | 0.0 | (0.0) | 0.0 | |||||||||
Other financial income (expense) | 0.5 | (0.6) | (0.2) | (1.0) | (1.5) | 0.3 | - | 0.6 | - | |||||||||
Other expense | (3.1) | (0.5) | (0.9) | (1.1) | (1.5) | - | - | (0.0) | (100.0) | |||||||||
Profit before taxes | 207.9 | 71.2 | 139.6 | 225.1 | 298.2 | 64.2 | (9.8) | 161.3 | +15.5 | |||||||||
(% of Revenues) | 30.3 | 39.7 | 37.9 | 39.0 | 37.9 | 38.0 | - | 41.3 | - | |||||||||
Income taxes | (50.3) | (19.7) | (37.3) | (62.7) | (83.5) | (16.8) | (14.7) | (43.1) | +15.5 | |||||||||
Net income | 157.6 | 51.5 | 102.3 | 162.4 | 214.7 | 47.4 | (8.0) | 118.1 | +15.4 | |||||||||
(% of Revenues) | 23.0 | 28.7 | 27.8 | 28.2 | 27.3 | 28.1 | - | 30.3 | - | |||||||||
Attributable to | ||||||||||||||||||
Chugai shareholders | 157.6 | 51.5 | 102.3 | 162.4 | 214.7 | 47.4 | (8.0) | 118.1 | +15.4 | |||||||||
Non-controlling interests | - | - | - | - | - | - | - | - | - | |||||||||
Earnings per share | ||||||||||||||||||
Basic (yen) | 95.95 | 31.37 | 62.26 | 98.84 | 130.66 | 28.84 | (8.1) | 71.86 | +15.4 | |||||||||
Diluted (yen) | 95.81 | 31.33 | 62.18 | 98.74 | 130.53 | 28.82 | (8.0) | 71.81 | +15.5 |
Other financial income (expense) includes net amount of FX related gains/losses.
Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. "Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.
Attachments
- Original document
- Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on 21 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2021 07:27:04 UTC.